Analysts Are Bullish on Top Healthcare Stocks: Capricor Therapeutics (CAPR), Adicet Bio (ACET)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Capricor Therapeutics (CAPR – Research Report), Adicet Bio (ACET – Research Report) and Hookipa Pharma (HOOK – Research Report) with bullish sentiments.

Capricor Therapeutics (CAPR)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics today and set a price target of $18.00. The company’s shares closed last Wednesday at $4.47.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.1% and a 31.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Actinium Pharmaceuticals, and Checkpoint Therapeutics.

Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $18.00.

See the top stocks recommended by analysts >>

Hookipa Pharma (HOOK)

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Hookipa Pharma, with a price target of $8.00.

According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -33.8% and a 17.6% success rate. CFA covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, LAVA Therapeutics, and Adagene.

Currently, the analyst consensus on Hookipa Pharma is a Moderate Buy with an average price target of $8.00, implying an 806.8% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CAPR:

• Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
• Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
• Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
• Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
• Capricor, Nippon Shinyaku enter commercialization, distribution partnership